Apixaban Dosing and Hyperkalemia in an Older Adult with HFrEF and CKD
A 78-year-old woman weighing 55 kg with heart failure and reduced ejection fraction (EF 30%) and atrial fibrillation is admitted with dizziness and poor oral intake. Her serum creatinine is 1.7 mg/dL (baseline 1.5 mg/dL), potassium 5.9 mEq/L, and eGFR 24 mL/min/1.73 m². Blood pressure is 98/60 mmHg and heart rate 58 beats/min. Her medications are apixaban 5 mg twice daily, sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, furosemide 40 mg daily, and carvedilol 6.25 mg twice daily. She denies bleeding. The ECG shows no peaked T waves or widened QRS. The team must decide whether the apixaban dose is correct, how to manage the potassium, and which heart failure medications to adjust without causing decompensation.
1. Calculate the creatinine clearance and determine the appropriate apixaban dose.
Read the worked answer
Using Cockcroft-Gault: CrCl = (140 − 78) × 55 / (72 × 1.7) = 62 × 55 / 122.4 ≈ 27.9 mL/min. For apixaban in nonvalvular atrial fibrillation, the dose is reduced to 2.5 mg twice daily when at least two of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. This patient meets two criteria - weight 55 kg and creatinine 1.7 mg/dL - so the correct dose is 2.5 mg twice daily, not 5 mg twice daily. Her CrCl of about 28 mL/min is above the threshold for avoidance but supports dose reduction. The current 5 mg twice daily dose is therefore too high and increases bleeding risk, especially with acute kidney injury and low oral intake. The dose should be corrected, and renal function, hemoglobin, and bleeding signs monitored.
2. Prioritize the management of potassium 5.9 mEq/L in this patient.
Read the worked answer
A potassium of 5.9 mEq/L is severe and requires immediate management even without ECG changes. The first steps are to stop spironolactone and hold sacubitril/valsartan, because both raise potassium and the patient has acute kidney injury and poor intake. Obtain a repeat ECG and place the patient on continuous cardiac monitoring. If ECG changes develop, give intravenous calcium for membrane stabilization. To shift potassium intracellularly, give insulin with glucose and consider nebulized salbutamol. A potassium binder can be used to remove potassium, and furosemide may be continued cautiously if volume status allows, but the patient is hypotensive and may be volume-depleted, so aggressive diuresis is risky. Recheck potassium and creatinine within 2 to 4 hours. Do not simply stop all heart failure therapy permanently; the goal is to treat the acute precipitant and reintroduce disease-modifying drugs at lower doses when potassium and renal function stabilize.
3. What monitoring and discharge plan would you recommend?
Read the worked answer
The patient needs telemetry, serial potassium and creatinine, daily weights, and blood pressure monitoring. Review all potassium-raising drugs, including over-the-counter NSAIDs and potassium-containing salt substitutes. Correct the apixaban dose to 2.5 mg twice daily and reassess renal function after volume status is clarified; if renal function deteriorates further, re-evaluate anticoagulation. Sacubitril/valsartan and spironolactone should be restarted sequentially when potassium is below 5.0 mEq/L and the patient is eating, with lower doses and early follow-up. Carvedilol may be continued if she is not bradycardic or hypotensive. Provide a clear heart failure action plan, dietary potassium advice, and follow-up within one week. Document the dose-reduction criteria for apixaban so the incorrect dose is not resumed at discharge.